Sangamo Therapeutics’ investigational gene therapy appears to improve kidney function at 52 weeks for patients with a rare genetic disorder.  | Sangamo Therapeutics’ investigational gene therapy ...

Pfizer’s anti-TFPI antibody marstacimab has been approved by the FDA to treat haemophilia ... in patients aged 12 and older and is the first drug in the anti-TFPI class to be approved in ...

May was a productive month for the FDA, with multiple drug approvals spanning a range of therapeutic areas, including chronic obstructive pulmonary disease (COPD), plaque psoriasis, and hemophilia A.

The US Food and Drug ... Pfizer-BioNTech’s Comirnaty, are mRNA-based, Novavax’s vaccine is protein-based and takes longer to manufacture. Moderna this month withdrew an application seeking ...

Arvinas and Pfizer have filed for U.S. Food and Drug Administration approval of their proposed breast-cancer drug vepdegestrant in certain patients with estrogen-receptor mutations. Arvinas on ...

Pfizer isn’t stopping to smell the roses on its speed run to secure a full FDA approval for its Braftovi combination therapy. After securing a unique accelerated approval not quite six months ...

Bayer has taken another step toward achieving its €3 billion peak sales estimate for androgen receptor inhibitor Nubeqa, scoring an FDA ... Pfizer and Astellas’ powerhouse Xtandi, which was ...

In the past 60 days, Pfizer’s earnings estimates have risen from $2.66 to $2.92 per share for 2024, while that for 2025 has increased from $2.86 to $2.94. PFE shares have lost 12.4% in the past ...

A precision oncology Pfizer drug now has clinical ... It was first approved in 2018 for treating advanced melanoma with that genetic signature. Late last year, the FDA expanded Braftovi’s ...

US Food and Drug ... approval for those who need it most,” said Kayvon Modjarrad, MD, PhD, executive director of Viral Vaccines and Immunology Vaccine Research and Development at Pfizer.

The drug is marketed in China under the brand name DOVBLERON, by Innovent Biologics. Pfizer's Xalkori, Roche's Rozlytrek, and Bristol-Myers Squibb Co.'s Augtyro are the FDA-approved medications ...

(Reuters) -The U.S. Food and Drug Administration has approved Moderna's next-generation ... While Moderna's shots, as well as Pfizer-BioNTech's Comirnaty, are mRNA-based, Novavax's vaccine is ...